Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CD70, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD70 also known as CD27 ligand or CD27L is a type II transmembrane protein with a molecular mass of approximately 30 kDa. It belongs to the tumor necrosis factor (TNF) superfamily and is encoded by the CD70 gene. The expression of CD70 occurs mainly on activated T and B cells dendritic cells and some NK cells but not on resting lymphocytes. In addition CD70 expression is observed in certain malignancies and inflammatory conditions.
Biological function summary
CD70 plays an essential role in the regulation of immune responses. It does this by binding to its receptor CD27 forming a receptor-ligand complex that triggers signaling pathways vital for T cell proliferation survival and differentiation. This interaction also influences the production of immunoglobulins by B cells. CD70-CD27 signaling is particularly important in shaping adaptive immunity enhancing the body's ability to respond to pathogens effectively.
Pathways
CD70 is integral in the activation of the NF-κB and MAPK pathways. These pathways are activated upon the interaction of CD70 with CD27 promoting cell survival proliferation and pro-inflammatory cytokine production. Other proteins related to CD70 through these pathways include TRAF2 and TRAF3 which are essential for downstream signaling events that modulate immune responses.
CD70 has been implicated in autoimmune diseases and certain cancers. For instance it plays a role in the pathogenesis of lupus by contributing to abnormal immune activation. Overexpression of CD70 is also associated with various cancers such as renal cell carcinoma where it can support tumor cell growth and immune evasion. Through these conditions CD70 interacts with proteins like BCL-2 in cancer affecting cell survival pathways while its interaction with CD27 influences the immune deregulation seen in lupus.
